
VitriLife Technology
The First Scalable Vitrification Platform for Biologics
VitriLife® is the first commercially scalable vitrification platform designed to stabilize sensitive biologics at industrial scale — without relying on freeze-drying. Our proprietary process enables shelf-stable, high-performance drug products that are easier to store, ship, and formulate.
Technology Highlights
-
A scalable alternative to lyophilization, offering enhanced stability and reproducibility
-
Immobilizes biologics in a foamed sugar-glass matrix to prevent molecular degradation
-
Preserves structure and activity by arresting rotational and translational motion
-
Extends shelf life and improves activity yields over time
-
Retains higher titer after drying and storage, minimizing potency loss
-
Reduces cold chain burden, cutting packaging and logistics costs
-
Supports micronization, enabling powder conversion without damaging the product
-
Compatible with combination products, including multi-component formulations
-
Reconstitutes instantly at the point of use — no lengthy prep or mixing

Formulation expertise across temperature-sensitive biologics
-
Vaccines
-
Monoclonal Antibodies
-
Hormones
-
Growth Factors
-
Therapeutic Proteins
-
Biosimilars
-
Live Biotherapeutic Products (LBPs)
Technology Comparison

VitriLife® supports both bulk and vial-based production formats
